You are here

CAR-T

Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T

Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T

Endpoints

Xyphos Biosciences

Flag link:

NHS, Gilead reach agreement for Yescarta

NHS, Gilead reach agreement for Yescarta

BioCentury

Gilead Sciences

Flag link:

Insight: How Novartis built a ‘money-filled moat’ to market Kymriah

Insight: How Novartis built a ‘money-filled moat’ to market Kymriah

Biopharma Reporter

Flag link:

Allogene IPO could be year's largest biotech listing on NASDAQ

Allogene IPO could be year's largest biotech listing on NASDAQ

BioCentury

Flag link:

Loyola is working on a new and improved CAR-T product, looking to overcome high-frequency side effects

Loyola is working on a new and improved CAR-T product, looking to overcome high-frequency side effects

Endpoints

Loyola University

drug development

Flag link:

NICE rejects Novartis’ CAR-T in adult lymphoma

NICE rejects Novartis’ CAR-T in adult lymphoma

Pharmaforum

diffuse large B-cell lymphoma

Flag link:

Allogene Therapeutics Announces Filing For IPO

Allogene Therapeutics Announces Filing For IPO

CP Wire

Flag link:

Atara brings another experienced investigator onto its off-the-shelf CAR-T quest in latest collaboration

Atara brings another experienced investigator onto its off-the-shelf CAR-T quest in latest collaboration

Endpoints

Flag link:

Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US

Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US

Biopharma Dive

Flag link:

Juno investors eke out $24M settlement in lawsuit over CAR-T trial deaths

Juno investors eke out $24M settlement in lawsuit over CAR-T trial deaths

Fierce Pharma

Juno Therapeutics

Flag link:

UK rejects Gilead's CAR-T cancer cell therapy as too expensive

UK rejects Gilead's CAR-T cancer cell therapy as too expensive

Reuters

Gilead Sciences

Flag link:

Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe

Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe

Endpoints

drug manufacturing

Flag link:

Does CAR-T Therapy Have a Payment Problem?

Does CAR-T Therapy Have a Payment Problem?

BioSpace

Flag link:

After a hiring blitz, where is Mustang's CAR-T manufacturing headed?

After a hiring blitz, where is Mustang's CAR-T manufacturing headed?

Biopharma Dive

Flag link:

Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer

Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer

Forbes

Flag link:

Kymriah Manufacturing Issues Spell Trouble for Commercialization of Novartis CAR-T Therapy

Kymriah Manufacturing Issues Spell Trouble for Commercialization of Novartis CAR-T Therapy

Xtalks

drug manufacturing

Flag link:

Celgene tweaks trial of myeloma CAR-T bb2121, raising dose

Celgene tweaks trial of myeloma CAR-T bb2121, raising dose

Fierce Biotech

clinical trials

Multiple Myeloma

Flag link:

Novartis partners with French CDMO to bolster CAR-T supply

Novartis partners with French CDMO to bolster CAR-T supply

Biopharma Dive

Flag link:

Gilead’s Kite taps Eisai cancer vet Amoroso to lead the charge for CAR-T sales

Gilead’s Kite taps Eisai cancer vet Amoroso to lead the charge for CAR-T sales

Fierce Pharma

Gilead Sciences

Flag link:

After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr

After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr

Endpoints

Flag link:

Pages